Bessemer Group’s Lexeo Therapeutics LXEO Stock Holding History

Bessemer Group’s Portfolio LXEO Stock Details LXEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,380	Closed	-$24K	–	2615
2025 Q4	$24K	Buy	+2,380	New	+$21.7K	﹤0.01%	1824

Other funds holding LXEO

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bessemer Group's LXEO Position: Q1 2026 in Review

Bessemer Group sold out of Lexeo Therapeutics (LXEO) in Q1 2026, closing a stake of 2,380 shares — an estimated $24K sold.

Bessemer Group first reported a position in LXEO in Q4 2025 and held it in 1 quarter. The position peaked at $24K in Q4 2025. 139 funds tracked by Wall St. Rank hold LXEO as of Q1 2026.

Bessemer Group reported no remaining Lexeo Therapeutics position as of Q1 2026 after selling out during the quarter.
Bessemer Group sold 2,380 Lexeo Therapeutics shares in Q1 2026, an estimated $24K.
Bessemer Group first reported a position in Lexeo Therapeutics in Q4 2025 and held it in 1 quarter.
Bessemer Group's Lexeo Therapeutics position peaked at $24K in Q4 2025.
139 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q1 2026.

Based on Bessemer Group's 13F filing for Q1 2026, filed 6 May 2026.